Table 1.

Baseline immune status in the according-to-protocol cohorts and subsets.

Study		US			Thailand			Puerto Rico
		Adults			Adults			Child (< 12 yoa)			Adult/Adolescent(≥ 12 yoa)				All
		total	primed#		total	primed*		total	primed#		total	primed#		total	primed#
Subjects	Treatment	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%
ATP cohort	F17/Pre	20	4	20	-	-	-	-	-	-	-	-		-	-
	F17	20	4	20	39	34	87	27	14	52	19	16	84	177	91	51
	F19	18	3	17	39	38	97	28	10	36	16	14	88	155	94	61
	Placebo	19	3	16	40	37	93	29	15	52	16	15	94	175	101	58
	Total	77	14	18	118	109	92	84	39	46	51	45	88	507	286	56
T-cell analysis (ICS@)	F17/Pre	20	4	20	-	-	-	-	-	-	-	-		-	-
	F17	19	4	21	24	23	96	22	11	50	11	9	82	33	20	61
	F19	17	3	18	22	21	96	23	7	30	12	10	83	35	17	49
	Placebo	19	3	16	23	22	96	21	14	67	11	10	91	32	24	75
	Total	75	14	19	69	66	96	66	32	49	34	29	85	100	61	61
B-cell analysis	F17/Pre	18	3	17	-	-	-	-	-	-	-	-		-	-	-
	F17	19	4	21	12	-	-	-	-	-	18	15	83	-	-	-
	F19	15	2	13	8	-	-	-	-	-	15	14	93	-	-	-
	Placebo	17	3	18	-	-	-	-	-	-	15	14	93	-	-	-
	Total	69	12	17	20	-	-	-	-	-	48	43	90	-	-	-

ATP, according to protocol. yoa, years of age. ICS, intracellular cytokine staining. N, number of subjects with available results for the respective analysis at baseline (numbers may vary by the DENV serotype analysed). ^#Seropositivity rate to DENV was defined as the percentage of subjects with neutralizing antibody (nAb) titers to at least one DENV serotype ≥ 1:10 dilution at pre-vaccination. *Seropositivity rate to DENV or Japanese encephalitis virus (JEV) was defined as the percentage of subjects with nAb titers to at least one DENV serotype or JEV ≥ 1:10 dilution at pre-vaccination. ^@Numbers are indicated for the ICS assay using infected cell lysates, the ICS assay using peptide-pool stimulation and the IFN-γ ELISPOT assay described in the current report were performed for 15 US subjects (of whom 13 were vaccinated) and 13 US subjects (of whom 11 were vaccinated), respectively.